Bayer vs PepsiCo: Revenue, Profit and Business Model
Bayer reported ~$51.5B of revenue in FY2025 and a net loss of ~$4.1B. PepsiCo reported $93.9B of revenue in FY2025 and $8.2B of net income.
Latest financial snapshot
Financial summary
Bayer
Bayer's accounts still carry the 2018 Monsanto acquisition. FY2025 sales were ~$51.5 billion (EUR 45,575 million), down 2.2 percent as reported and up 1.1 percent adjusted for currency and portfolio. EBITDA before special items was ~$11 billion (EUR 9.7 billion) and free cash flow ~$2.35 billion (EUR 2,084 million), yet the group reported an EBIT of minus ~$1.22 billion (EUR 1,077 million) and a net loss of ~$4.09 billion (EUR 3,620 million), because other operating expenses net of income reached minus ~$8.34 billion (EUR 7,377 million), mainly litigation provisions. Net financial debt fell 8.5 percent to ~$33.7 billion (EUR 29,843 million). The dividend has stayed at the legally required minimum of EUR 0.11 per share since 2023, so cash goes to debt and settlements rather than shareholders.
PepsiCo
PepsiCo grew net revenue from $62.8 billion in 2016 to $93.9 billion in 2025, but growth slowed to 0.4% in 2024 and 2.3% in 2025 (1.7% organic) as North American snack volumes declined. Fiscal 2025 net income was $8.24 billion, down 14%, reflecting a roughly $2 billion impairment mainly on Rockstar. In 2026 the picture improved on the top line: Q1 net revenue rose 8.5% and Q2 rose 6.4% to $24.18 billion, helped by acquisitions, currency and international volume. Q2 2026 net income was $2.98 billion versus $1.26 billion a year earlier. For full-year 2026 PepsiCo guided to 2-4% organic revenue growth and 4-6% core constant-currency EPS growth.
Revenue and profit by year
Bayer
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | ~$51.5B | ~-$4.1B | -7.9% | -2.2% | Source |
| FY2024 | ~$52.7B | ~-$2.9B | -5.5% | -2.2% | Source |
| FY2023 | ~$53.8B | ~-$3.3B | -6.2% | -6.1% | Source |
| FY2022 | ~$57.3B | ~$4.7B | 8.2% | +15.1% | Source |
| FY2021 | ~$49.8B | ~$1.1B | 2.3% | +6.5% | Source |
| FY2020 | ~$46.8B | ~-$11.9B | -25.4% | -4.9% | Source |
| FY2019 | ~$49.2B | ~$4.6B | 9.4% | +10.0% | Source |
| FY2018 | ~$44.7B | ~$1.9B | 4.3% | +13.1% | Source |
| FY2017 | ~$39.6B | ~$8.3B | 21.0% | — | Source |
PepsiCo
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $93.9B | $8.2B | 8.8% | +2.3% | Source |
| FY2024 | $91.9B | $9.6B | 10.4% | +0.4% | Source |
| FY2023 | $91.5B | $9.1B | 9.9% | +5.9% | Source |
| FY2022 | $86.4B | $8.9B | 10.3% | +8.7% | Source |
| FY2021 | $79.5B | $7.6B | 9.6% | +12.9% | Source |
| FY2020 | $70.4B | $7.1B | 10.1% | +4.8% | Source |
| FY2019 | $67.2B | $7.3B | 10.9% | +3.9% | Source |
| FY2018 | $64.7B | $12.5B | 19.4% | +1.8% | Source |
| FY2017 | $63.5B | $4.9B | 7.6% | +1.2% | Source |
| FY2016 | $62.8B | $6.3B | 10.1% | — | Source |
Where the revenue comes from
Bayer
- Crop Science
about 47%
Seeds, biotech traits, crop protection chemicals and digital farming produced ~$24.4 billion (EUR 21,622 million) of 2025 sales, led by Corn Seed and Traits at ~$8.08 billion (EUR 7,149 million).
- Pharmaceuticals
about 39%
Prescription medicines produced ~$20.1 billion (EUR 17,829 million) of 2025 sales, with Eylea at ~$3.51 billion (EUR 3,110 million), Nubeqa at ~$2.7 billion (EUR 2,385 million), Xarelto at ~$2.65 billion (EUR 2,344 million) and the Mirena family at ~$1.54 billion (EUR 1,366 million).
- Consumer Health
about 13%
Over-the-counter brands produced ~$6.56 billion (EUR 5,802 million) of 2025 sales across nutritionals, allergy and cold, pain and cardio, digestive health and dermatology.
PepsiCo
- PepsiCo Foods North America (Frito-Lay and Quaker)~30%
Savory snacks, oats, bars and dips sold to US and Canadian retailers and foodservice; about $27.7 billion combined in 2024.
- PepsiCo Beverages North America~30%
Finished drinks, fountain syrup and concentrate, including Pepsi, Mountain Dew, Gatorade and partner brands; about $27.8 billion in 2024.
- International (Latin America, Europe, AMESA, Asia Pacific)~40%
Locally made snacks such as Sabritas, Walkers and Kurkure plus beverage concentrate sold to franchise bottlers and company-run beverage operations.
Business model and strategy
Bayer
How it makes money
Bayer runs two very different businesses plus a consumer brand portfolio. Pharmaceuticals spent ~$3.91 billion (EUR 3,456 million) on research and development in 2025 to develop and launch patented specialty medicines in oncology, cardiovascular and renal disease, women's health and radiology, and sells them to hospitals and specialist prescribers at high gross margins.
Growth strategy
After a strategic review in March 2024 Bayer decided not to break itself up, keeping the three divisions together while it works on litigation and debt. Growth therefore has to come from inside: scaling Nubeqa, which reached ~$2.7 billion (EUR 2,385 million) of sales in 2025, and Kerendia at ~$937 million (EUR 829 million); launching Lynkuet, Beyonttra and Hyrnuo; filing gadoquatrane in radiology;
Competitive advantage
Bayer's strongest position is in seeds and traits. Corn Seed and Traits alone generated ~$8.08 billion (EUR 7,149 million) of sales in 2025, up 9.0 percent as reported, because growers buy hybrid seed together with the trait packages licensed into it and then buy matching crop protection chemistry. Changing seed supplier means changing agronomic practice mid-rotation, which slows share loss.
PepsiCo
How it makes money
PepsiCo makes money by manufacturing and selling branded snacks, packaged foods and beverages to retailers, foodservice operators and independent bottlers. It reports through regional segments: PepsiCo Foods North America (Frito-Lay and Quaker, combined in 2025), PepsiCo Beverages North America (PBNA), Latin America, Europe, Africa/Middle East/South Asia (AMESA) and Asia Pacific.
Growth strategy
PepsiCo's current growth strategy has four parts: affordability (price cuts of up to 15% on Lay's, Tostitos, Doritos and Cheetos in February 2026), portfolio shift toward better-for-you and functional brands through acquisitions such as Siete (2025), poppi ($1.95 billion, closed May 2025) and Sabra, cost reduction (three US plant closures, SKU rationalization and a review of North American supply chain and go-to-mark…
Competitive advantage
PepsiCo's advantage is scale in savory snacks combined with a large beverage business and a direct-store-delivery network. Frito-Lay brands such as Lay's, Doritos and Cheetos lead the US salty snack aisle, and DSD lets PepsiCo control merchandising and restocking in grocery, mass and convenience stores.
Questions about Bayer vs PepsiCo
Which company has higher revenue — Bayer AG or PepsiCo, Inc.?
Bayer AG reported ~$51.5B (FY2025), while PepsiCo, Inc. reported $93.9B (FY2025). By last reported revenue, PepsiCo, Inc. is the larger business, with Bayer AG reporting a smaller revenue base.
What is the market cap of Bayer AG vs PepsiCo, Inc.?
Bayer AG's market capitalisation stands at $47.1B, while PepsiCo, Inc.'s is $175.0B. PepsiCo, Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Bayer AG.
Which is more financially efficient — Bayer AG or PepsiCo, Inc.?
Bayer AG generates $585k / employee in revenue per employee, while PepsiCo, Inc. generates $307k / employee. Bayer AG shows higher revenue efficiency per headcount, though this reflects business model differences — capital-light software companies routinely outperform labour-intensive manufacturers on this metric.
How do Bayer AG and PepsiCo, Inc. make money?
Bayer AG and PepsiCo, Inc. generate revenue in fundamentally different ways. Bayer AG: Bayer runs two very different businesses plus a consumer brand portfolio. PepsiCo, Inc.: PepsiCo makes money by manufacturing and selling branded snacks, packaged foods and beverages to retailers, foodservice operators and independent bottlers.
Which company is valued higher relative to revenue — Bayer AG or PepsiCo, Inc.?
On a price-to-sales (P/S) basis, Bayer AG trades at 0.9x P/S and PepsiCo, Inc. at 1.9x P/S. PepsiCo, Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Bayer AG. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is Bayer AG bigger than PepsiCo, Inc.?
By last reported revenue, PepsiCo, Inc. ($93.9B (FY2025)) is the larger company compared to Bayer AG (~$51.5B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the Bayer vs PepsiCo overview